SCHEMBL1134481

SCHEMBL1134481

CC(C)Oc1cccc(NC(=O)c2cncc(Cl)n2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN2A Q99250 2/20 0.64
▸ SCN10A Q9Y5Y9 2/20 0.64
▸ PLAU P00749 2/20 0.51
▸ F2 P00734 1/20 0.51
▸ PLG P00747 1/20 0.51
▸ PLAT P00750 1/20 0.51
▸ KLKB1 P03952 1/20 0.51
▸ PRSS1 P07477 1/20 0.51
▸ CSF1R P07333 5/20 0.50
▸ GRM4 Q14833 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ CNR1 P21554 1/20 0.49
▸ USP36 Q9P275 1/20 0.48
▸ GRM5 P41594 1/20 0.48
▸ RET P07949 1/20 0.47
▸ PDGFRB P09619 1/20 0.47
▸ KIT P10721 1/20 0.47
▸ SRC P12931 1/20 0.47
▸ PDGFRA P16234 1/20 0.47
▸ FLT1 P17948 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2064811 0.82 SCN2A (0.70) SCN2ASCN10ACSF1RSMN1; SMN2GRM5
SCHEMBL28491336 0.81 SMN1; SMN2 (0.58) SCN2ASCN10AGRM4SMN1; SMN2GRM5
SCHEMBL1134528 0.78 SCN2A (0.67) SCN2ASCN10APLAUPLGSMN1; SMN2
SCHEMBL1135585 0.76 SCN2A (0.52) SCN2ASCN10A
SCHEMBL28491335 0.75 KCNQ3 (0.57) SMN1; SMN2GRM5
SCHEMBL2098030 0.75 ALDH1A1 (0.66) PLAUF2PLGPLATKLKB1
SCHEMBL4376910 0.75 SCN2A (0.52) SCN2ASCN10APLAUF2PLG
SCHEMBL11587410 0.74 KMT2A (0.71) PLAUSMN1; SMN2
SCHEMBL2093226 0.73 CA2 (0.58) PLAUF2PLGPLATKLKB1
SCHEMBL2093222 0.73 CA2 (0.58) PLAUF2PLGPLATKLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2700639-A1 Selective ligands for the neuronal nicotinic receptors and uses thereof Abbvie Inc. (US) 2014-02-26 — — EP disclosed
US-8648084-B2 Selective substituted pyrazine ligands for neuronal nicotinic receptors ABBVIE INC. (US) 2014-02-11 — — US disclosed
US-20120190692-A1 SELECTIVE SUBSTITUTED PYRIDINE LIGANDS FOR NEURONAL NICOTINIC RECEPTORS ABBVIE INC. 2012-07-26 — — US disclosed
US-8148408-B2 Selective substituted pyridine ligands for neuronal nicotinic receptors ABBOTT LABORATORIES (US) 2012-04-03 — — US disclosed
EP-2285810-A1 SELECTIVE LIGANDS FOR THE NEURONAL NICOTINIC RECEPTORS AND USES THEREOF Abbott Laboratories (US) 2011-02-23 — — EP disclosed
WO-2009137308-A1 SELECTIVE LIGANDS FOR THE NEURONAL NICOTINIC RECEPTORS AND USES THEREOF ABBOTT LABORATORIES (US) 2009-11-12 — — WO disclosed
US-20090281118-A1 Selective Ligands for the Neuronal Nicotinic Receptors and Uses Thereof ABBOTT LABORATORIES (US) 2009-11-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190692-A1 SELECTIVE SUBSTITUTED PYRIDINE LIGANDS FOR NEURONAL NICOTINIC RECEPTORS CHRNA4, CHRNB4, CHRNA2 SCN2A 106/4885SCN10A 152/4885PLAU 4747/4885
US-20090281118-A1 Selective Ligands for the Neuronal Nicotinic Receptors and Uses Thereof CHRNA4, CHRNB4, CHRNA2 SCN2A 113/4885SCN10A 139/4885PLAU 4539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback